Truist Securities Downgrades Harmony Biosciences Holdings, Inc. (HRMY) to Hold After Patent Trial Developments

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is among the 20 Best Investments in 2026.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the best investment stocks on our list.

TheFly reported on February 20 that Truist Securities downgraded HRMY from Buy to Hold following the conclusion of its bench trial against Paragraph IV filer AET Pharma. The analyst pointed out that Judge Hall's early post-trial comments raised the possibility of Harmony's case ending badly. The company consequently voiced concerns over the Wakix franchise, pointing out that there was a high risk and a good chance that generic rivals would join the market before 2029.

On February 17, Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) announced that the U.S. Food and Drug Administration (FDA) had approved its supplemental New Drug Application for WAKIX (pitolisant) tablets to treat cataplexy in children with narcolepsy who are six years of age or older. Regardless of whether a child has cataplexy or not, Wakix is now the first and only FDA-approved non-scheduled therapy for narcolepsy. This achievement expands the range of therapy options available to patients of all ages by enabling physicians to prescribe WAKIX to patients six years of age and older for excessive daytime sleepiness, cataplexy, or both.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a biopharmaceutical company developing therapies for rare neurological disorders, focusing on innovative treatments for conditions like narcolepsy and other sleep-related diseases.

While we acknowledge the potential of HRMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the

Disclosure: None.